Base de dados : MEDLINE
Pesquisa : D02.455.526.728.650.594 [Categoria DeCS]
Referências encontradas : 6876 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 688 ir para página                         

  1 / 6876 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29177308
[Au] Autor:Fang K; Wu S; Dong G; Wu Y; Chen S; Liu J; Wang W; Sheng C
[Ad] Endereço:School of Pharmacy, East China University of Science and Technology, Shanghai 200237, P. R. China. wwang@unm.edu.
[Ti] Título:Discovery of IDO1 and DNA dual targeting antitumor agents.
[So] Source:Org Biomol Chem;15(47):9992-9995, 2017 Dec 06.
[Is] ISSN:1477-0539
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The development of small molecules for cancer immunotherapy is highly challenging and indoleamine 2,3-dioxygenase 1 (IDO1) represents a promising target. Inspired by the synergistic effects between IDO1 inhibitors and traditional antitumor chemotherapeutics, the first orally active dual IDO1 and DNA targeting agents were designed by the pharmacophore fusion strategy. The bifunctional hybrids exhibited enhanced IDO1 enzyme inhibitory activity and in vitro cytotoxicity as compared to IDO1 inhibitor 1-methyl-tryptophan and DNA alkylating agent melphalan. In a murine LLC tumor model, the dual targeting agents demonstrated excellent antitumor efficacy, highlighting the advantages of this novel design strategy to improve the efficacy of small molecule cancer immunotherapy.
[Mh] Termos MeSH primário: Antineoplásicos/farmacologia
DNA de Neoplasias/efeitos dos fármacos
Inibidores Enzimáticos/farmacologia
Indolamina-Pirrol 2,3,-Dioxigenase/antagonistas & inibidores
Melfalan/farmacologia
Triptofano/análogos & derivados
[Mh] Termos MeSH secundário: Animais
Antineoplásicos/síntese química
Antineoplásicos/química
Linhagem Celular Tumoral
Proliferação Celular/efeitos dos fármacos
Relação Dose-Resposta a Droga
Descoberta de Drogas
Ensaios de Seleção de Medicamentos Antitumorais
Inibidores Enzimáticos/síntese química
Inibidores Enzimáticos/química
Seres Humanos
Imunoterapia
Indolamina-Pirrol 2,3,-Dioxigenase/metabolismo
Melfalan/síntese química
Melfalan/química
Camundongos
Estrutura Molecular
Neoplasias Experimentais/tratamento farmacológico
Relação Estrutura-Atividade
Triptofano/síntese química
Triptofano/química
Triptofano/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (1-methyltryptophan); 0 (Antineoplastic Agents); 0 (DNA, Neoplasm); 0 (Enzyme Inhibitors); 0 (Indoleamine-Pyrrole 2,3,-Dioxygenase); 0 (indoleamine 2,3-dioxygenase 1, human); 8DUH1N11BX (Tryptophan); Q41OR9510P (Melphalan)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE
[do] DOI:10.1039/c7ob02529g


  2 / 6876 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27771496
[Au] Autor:Cabrero M; Martin A; Briones J; Gayoso J; Jarque I; López J; Grande C; Heras I; Arranz R; Bernal T; Perez-Lopez E; López-Godino O; Conde E; Caballero D
[Ad] Endereço:Hematology Department, Hospital Universitario Salamanca and IBSAL (Instituto Biosanitario de Salamanca), Spain.
[Ti] Título:Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial.
[So] Source:Biol Blood Marrow Transplant;23(1):53-59, 2017 Jan.
[Is] ISSN:1523-6536
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We designed a phase II clinical trial including Y-90 ibritumomab-tiuxetan as part of a reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (AlloSCT) in high-risk non-Hodgkin lymphoma (Clinical Trials Identifier: NCT00644371). Eligible patients had high-risk relapsed/refractory aggressive lymphoma. The conditioning regimen consisted of rituximab 250 mg (days -21 and -14), Y-90 ibritumomab IV (.4 m Ci/kg, day -14), fludarabine 30 mg/m i.v. (days -3 and -2) plus melphalan 70 mg/m i.v. (days -3 and -2) or 1 dose of melphalan and thiotepa 5 mg/kg (day -8). Donors were related. Eighteen patients were evaluable. At the time of transplantation, responses were complete remission (CR) (n = 7, 39%), partial remission (n = 6, 33%) or refractory disease (n = 4, 28%). Y-90-ibritumomab infusions were well tolerated, with no adverse reactions. Nonrelapse mortality at 1 year was 28%. Median follow-up was 46 (range, 39 to 55) months. Estimated 1-year progression-free survival (PFS) was 50%, and 4-year overall survival (OS) and PFS were both 44.4%. CR at the moment of AlloSCT had significant impact on PFS (71% versus 27%, P = .046) and OS (71% versus 27%, P = .047). Our results show that Y-90-ibritumomab-tiuxetan as a component of RIC for AlloSCT is feasible in patients with high-risk B cell lymphoma. Development of phase III clinical trials is needed to clarify the contribution of radioimmunotherapy to RIC AlloSCT.
[Mh] Termos MeSH primário: Anticorpos Monoclonais/administração & dosagem
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Linfoma de Células B/terapia
Terapia de Salvação/métodos
Condicionamento Pré-Transplante/métodos
[Mh] Termos MeSH secundário: Adulto
Feminino
Transplante de Células-Tronco Hematopoéticas/métodos
Transplante de Células-Tronco Hematopoéticas/mortalidade
Seres Humanos
Linfoma de Células B/mortalidade
Masculino
Melfalan/administração & dosagem
Meia-Idade
Radioimunoterapia/métodos
Radioimunoterapia/mortalidade
Terapia de Salvação/mortalidade
Análise de Sobrevida
Tiotepa/administração & dosagem
Condicionamento Pré-Transplante/mortalidade
Transplante Homólogo
Vidarabina/administração & dosagem
Vidarabina/análogos & derivados
Radioisótopos de Ítrio/uso terapêutico
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Yttrium Radioisotopes); 4Q52C550XK (ibritumomab tiuxetan); 905Z5W3GKH (Thiotepa); FA2DM6879K (Vidarabine); P2K93U8740 (fludarabine); Q41OR9510P (Melphalan)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  3 / 6876 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:29231133
[Au] Autor:Mateos MV; Dimopoulos MA; Cavo M; Suzuki K; Jakubowiak A; Knop S; Doyen C; Lucio P; Nagy Z; Kaplan P; Pour L; Cook M; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Shelekhova T; Yoon SS; Iosava G; Fujisaki T; Garg M; Chiu C; Wang J; Carson R; Crist W; Deraedt W; Nguyen H; Qi M; San-Miguel J; ALCYONE Trial Investigators
[Ad] Endereço:From University Hospital of Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca (M.-V.M.), and Clínica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Pamplona (J.S
[Ti] Título:Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
[So] Source:N Engl J Med;378(6):518-528, 2018 02 08.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The combination of bortezomib, melphalan, and prednisone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. Daratumumab has shown efficacy in combination with standard-of-care regimens in patients with relapsed or refractory multiple myeloma. METHODS: In this phase 3 trial, we randomly assigned 706 patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation to receive nine cycles of bortezomib, melphalan, and prednisone either alone (control group) or with daratumumab (daratumumab group) until disease progression. The primary end point was progression-free survival. RESULTS: At a median follow-up of 16.5 months in a prespecified interim analysis, the 18-month progression-free survival rate was 71.6% (95% confidence interval [CI], 65.5 to 76.8) in the daratumumab group and 50.2% (95% CI, 43.2 to 56.7) in the control group (hazard ratio for disease progression or death, 0.50; 95% CI, 0.38 to 0.65; P<0.001). The overall response rate was 90.9% in the daratumumab group, as compared with 73.9% in the control group (P<0.001), and the rate of complete response or better (including stringent complete response) was 42.6%, versus 24.4% (P<0.001). In the daratumumab group, 22.3% of the patients were negative for minimal residual disease (at a threshold of 1 tumor cell per 10 white cells), as compared with 6.2% of those in the control group (P<0.001). The most common adverse events of grade 3 or 4 were hematologic: neutropenia (in 39.9% of the patients in the daratumumab group and in 38.7% of those in the control group), thrombocytopenia (in 34.4% and 37.6%, respectively), and anemia (in 15.9% and 19.8%, respectively). The rate of grade 3 or 4 infections was 23.1% in the daratumumab group and 14.7% in the control group; the rate of treatment discontinuation due to infections was 0.9% and 1.4%, respectively. Daratumumab-associated infusion-related reactions occurred in 27.7% of the patients. CONCLUSIONS: Among patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation, daratumumab combined with bortezomib, melphalan, and prednisone resulted in a lower risk of disease progression or death than the same regimen without daratumumab. The daratumumab-containing regimen was associated with more grade 3 or 4 infections. (Funded by Janssen Research and Development; ALCYONE ClinicalTrials.gov number, NCT02195479 .).
[Mh] Termos MeSH primário: Anticorpos Monoclonais/administração & dosagem
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Mieloma Múltiplo/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Anticorpos Monoclonais/efeitos adversos
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Bortezomib/administração & dosagem
Intervalo Livre de Doença
Feminino
Seguimentos
Seres Humanos
Infecção/induzido quimicamente
Infecção/mortalidade
Análise de Intenção de Tratamento
Estimativa de Kaplan-Meier
Masculino
Melfalan/administração & dosagem
Meia-Idade
Mieloma Múltiplo/mortalidade
Prednisona/administração & dosagem
Taxa de Sobrevida
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 4Z63YK6E0E (daratumumab); 69G8BD63PP (Bortezomib); Q41OR9510P (Melphalan); VB0R961HZT (Prednisone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171213
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMoa1714678


  4 / 6876 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29209924
[Au] Autor:Oosten LEM; Chamuleau MED; Thielen FW; de Wreede LC; Siemes C; Doorduijn JK; Smeekes OS; Kersten MJ; Hardi L; Baars JW; Demandt AMP; Stevens WBC; Nijland M; van Imhoff GW; Brouwer R; Uyl-de Groot CA; Kluin PM; de Jong D; Veelken H
[Ad] Endereço:Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. l.e.m.oosten@lumc.nl.
[Ti] Título:Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens.
[So] Source:Ann Hematol;97(2):255-266, 2018 Feb.
[Is] ISSN:1432-0584
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Burkitt lymphoma is an aggressive B cell malignancy accounting for 1-2% of all adult lymphomas. Treatment with dose-intensive, multi-agent chemotherapy is effective but associated with considerable toxicity. In this observational study, we compared real-world efficacy, toxicity, and costs of four frequently employed treatment strategies for Burkitt lymphoma: the Lymphome Malins B (LMB), the Berlin-Frankfurt-Münster (BFM), the HOVON, and the CODOX-M/IVAC regimens. We collected data from 147 adult patients treated in eight referral centers. Following central pathology assessment, 105 of these cases were accepted as Burkitt lymphoma, resulting in the following treatment groups: LMB 36 patients, BFM 19 patients, HOVON 29 patients, and CODOX-M/IVAC 21 patients (median age 39 years, range 14-74; mean duration of follow-up 47 months). There was no significant difference between age, sex ratio, disease stage, or percentage HIV-positive patients between the treatment groups. Five-year progression-free survival (69%, p = 0.966) and 5-year overall survival (69%, p = 0.981) were comparable for all treatment groups. Treatment-related toxicity was also comparable with only hepatotoxicity seen more frequently in the CODOX/M-IVAC group (p = 0.004). Costs were determined by the number of rituximab gifts and the number of inpatients days. Overall, CODOX-M/IVAC had the most beneficial profile with regards to costs, treatment duration, and percentage of patients completing planned treatment. We conclude that the four treatment protocols for Burkitt lymphoma yield nearly identical results with regards to efficacy and safety but differ in treatment duration and costs. These differences may help guide future choice of treatment.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Linfoma de Burkitt/tratamento farmacológico
Análise Custo-Benefício
Infecções por HIV/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Linfoma de Burkitt/complicações
Linfoma de Burkitt/economia
Linfoma de Burkitt/mortalidade
Carmustina/economia
Carmustina/uso terapêutico
Ciclofosfamida/economia
Ciclofosfamida/uso terapêutico
Citarabina/economia
Citarabina/uso terapêutico
Etoposídeo/economia
Etoposídeo/uso terapêutico
Feminino
Infecções por HIV/complicações
Infecções por HIV/economia
Infecções por HIV/mortalidade
Seres Humanos
Ifosfamida/economia
Ifosfamida/uso terapêutico
Masculino
Melfalan/economia
Melfalan/uso terapêutico
Metotrexato/economia
Metotrexato/uso terapêutico
Meia-Idade
Estadiamento de Neoplasias
Estudos Retrospectivos
Rituximab/economia
Rituximab/uso terapêutico
Análise de Sobrevida
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; MULTICENTER STUDY; OBSERVATIONAL STUDY
[Nm] Nome de substância:
04079A1RDZ (Cytarabine); 4F4X42SYQ6 (Rituximab); 6PLQ3CP4P3 (Etoposide); 8N3DW7272P (Cyclophosphamide); Q41OR9510P (Melphalan); U68WG3173Y (Carmustine); UM20QQM95Y (Ifosfamide); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180123
[Lr] Data última revisão:
180123
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171207
[St] Status:MEDLINE
[do] DOI:10.1007/s00277-017-3167-7


  5 / 6876 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29173979
[Au] Autor:Simon N; Coiteux V; Bruno B; Taque S; Charbonnier A; Souchet L; Vincent L; Yakoub-Agha I; Chalandon Y
[Ad] Endereço:Université de Lille, EA 7365, GRITA, groupe de recherche sur les formes injectables et les technologies associées, 59000 Lille, France; CHU de Lille, institut de pharmacie, 59000 Lille, France.
[Ti] Título:[Dose adaptation of the drugs used for hematopoietic stem-cell transplantation in patients with comorbidity: Obesity, chronic renal disease or hepatopathy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
[Ti] Título:Adaptation des doses de médicament des conditionnements de greffe de cellules souches hématopoïétiques dans des populations avec comorbidité : obésité, maladie rénale chronique ou hépatopathie : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)..
[So] Source:Bull Cancer;104(12S):S99-S105, 2017 Dec.
[Is] ISSN:1769-6917
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:In September 2016 in Lille, France, the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) organized the 7th Allogeneic Stem Cell Transplantation Clinical Practices Harmonization Workshop Series. Our work group focused on chemotherapy drug dose adaptation for hematopoietic stem cell transplantation patients presenting a comorbidity. The purpose of this workshop was to provide recommendations on chemotherapy drug dose adaptation for patient populations receiving hematopoietic stem cell transplantation who also had the following comorbidities: obesity, chronic kidney disease and hepatopathy.
[Mh] Termos MeSH primário: Transplante de Células-Tronco Hematopoéticas/normas
Imunossupressores/administração & dosagem
Hepatopatias
Obesidade
Insuficiência Renal Crônica
Condicionamento Pré-Transplante/normas
[Mh] Termos MeSH secundário: Adulto
Fatores Etários
Bussulfano/administração & dosagem
Criança
Comorbidade
Ciclofosfamida/administração & dosagem
Etoposídeo/administração & dosagem
França
Seres Humanos
Hepatopatias/epidemiologia
Melfalan/administração & dosagem
Obesidade/epidemiologia
Insuficiência Renal Crônica/epidemiologia
Sociedades Médicas
Inquéritos e Questionários
Tiotepa/administração & dosagem
Vidarabina/administração & dosagem
Vidarabina/análogos & derivados
Irradiação Corporal Total
[Pt] Tipo de publicação:CONSENSUS DEVELOPMENT CONFERENCE; JOURNAL ARTICLE; PRACTICE GUIDELINE; REVIEW
[Nm] Nome de substância:
0 (Immunosuppressive Agents); 6PLQ3CP4P3 (Etoposide); 8N3DW7272P (Cyclophosphamide); 905Z5W3GKH (Thiotepa); FA2DM6879K (Vidarabine); G1LN9045DK (Busulfan); P2K93U8740 (fludarabine); Q41OR9510P (Melphalan)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171228
[Lr] Data última revisão:
171228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE


  6 / 6876 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29187931
[Au] Autor:Fall S; Dieng F; Diouf C; Djiba B; Ndao AC; Ndiaye FSD
[Ad] Endereço:Unité d'Hématologie Clinique de l'Hôpital Aristide Le Dantec, Dakar, Sénégal.
[Ti] Título:[Diagnostic and evolutionary profile of multiple myeloma in Senegal: monocentric study conducted from 2005 to 2016].
[Ti] Título:Profil diagnostique et évolutif du myélome multiple au Sénégal: étude monocentrique de 2005 à 2016..
[So] Source:Pan Afr Med J;27:262, 2017.
[Is] ISSN:1937-8688
[Cp] País de publicação:Uganda
[La] Idioma:fre
[Ab] Resumo:Introduction: Accessibility to innovative multiple myeloma therapies is limited in sub-Saharan Africa. This study aimed to describe the diagnostic and evolutionary features observed during treatment of our patients with myeloma. Methods: We conducted a retrospective, descriptive, analytical study (2005 - 2016) of patients with myeloma included in the study based on International Myeloma Working Group (IMWG) Criteria (2003,2014) at the Hopital Aristide Le Dantec (Senegal). Results: We collected data from 136 medical records (69 men, 67 women) of patients with an average age of 59 years ± 10.1 years, who were less than 65 years of age in 69.1% of cases. Tell-tale signs included bone pain (96.3%), renal failure (36.8%), infection (23.5%), pathological fracture (17.6%), spinal cord compression (16.9%) and malignant hypercalcaemia (16.2%). Isotopic antiglobulin test showed that anti-IgG could be detected in 61.3% of cases and Kappa in 65% of cases. Patients were classified stage III (59.4%) and I-II (40.6%)of the index staging system. The median survival of patients under conventional traitement (Méphalan-Prédnisone: 67.6%, innovative: 5.9%) was 20 months (1-78 months). Survival rates are better in the absence of neurological and infectious complications and for patients with score I-II of the index Staging System. Conclusion: In our study, multiple myeloma was frequently diagnosed before age 65, at advanced stage of tumor mass. Early detection and access to adequate therapies could improve overall survival.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Acesso aos Serviços de Saúde
Mieloma Múltiplo/terapia
[Mh] Termos MeSH secundário: Idoso
Anticorpos Anti-Idiotípicos/imunologia
Feminino
Seres Humanos
Masculino
Melfalan/administração & dosagem
Meia-Idade
Mieloma Múltiplo/diagnóstico
Mieloma Múltiplo/patologia
Estadiamento de Neoplasias
Prednisona/administração & dosagem
Estudos Retrospectivos
Senegal
Taxa de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Anti-Idiotypic); 0 (anti-IgG); Q41OR9510P (Melphalan); VB0R961HZT (Prednisone)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171219
[Lr] Data última revisão:
171219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE
[do] DOI:10.11604/pamj.2017.27.262.13164


  7 / 6876 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28696028
[Au] Autor:Ozuah NW; Dahmoush HM; Grant FD; Lehmann LE; LaCasce AS; Billett AL; Margossian SP
[Ad] Endereço:Department of Pediatric Hematology/Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts.
[Ti] Título:Pretransplant functional imaging and outcome in pediatric patients with relapsed/refractory Hodgkin lymphoma undergoing autologous transplantation.
[So] Source:Pediatr Blood Cancer;65(1), 2018 Jan.
[Is] ISSN:1545-5017
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Pretransplant functional imaging (FI), particularly a negative positron emission tomography (PET), is a strong predictor of outcome in adults with relapsed or refractory Hodgkin lymphoma (HL), but data in pediatrics are limited. METHODS: The medical records of 49 consecutive pediatric patients, who received autologous transplant at a single institution, were retrospectively analyzed. All patients had either gallium or PET scan before transplant and were conditioned with carmustine, etoposide, cytarabine, and melphalan (BEAM). Deauville scores were retrospectively assigned for patients with PET (score ≥ 4 positive). RESULTS: Of the 49 patients (median age, 16.2 years), 41 (84%) were pretransplant FI negative and eight (16%) were pretransplant FI positive, after first- to fourth-line salvage therapy, and a median of two salvage cycles. Eighteen patients (37%) received posttransplant radiation. At a median follow up of 46 months, 45 patients (92%) were alive and disease free, and there were three nonrelapse deaths and only one relapse death (Deauville score of 5). The 4-year progression-free survival (PFS) for the entire cohort was 92% (95% confidence interval [CI]: 78-97), and PFS based on pretransplant disease status was 95% (95% CI: 82-99%) in the negative FI group versus 75% (95% CI: 31-93) if positive FI (P = 0.057). CONCLUSION: Our analysis revealed outstanding outcomes for children and adolescents with relapsed/refractory HL. There were too few relapses to identify the predictive value of pretransplant metabolic status, but pediatric patients with relapsed/refractory HL and a negative pretransplant FI had excellent survival.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Doença de Hodgkin
Tomografia por Emissão de Pósitrons
Cuidados Pré-Operatórios
Transplante de Células-Tronco
[Mh] Termos MeSH secundário: Adolescente
Adulto
Autoenxertos
Carmustina/administração & dosagem
Criança
Citarabina/administração & dosagem
Intervalo Livre de Doença
Feminino
Seguimentos
Doença de Hodgkin/diagnóstico por imagem
Doença de Hodgkin/mortalidade
Doença de Hodgkin/terapia
Seres Humanos
Masculino
Melfalan/administração & dosagem
Podofilotoxina/administração & dosagem
Estudos Retrospectivos
Taxa de Sobrevida
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
04079A1RDZ (Cytarabine); L36H50F353 (Podophyllotoxin); Q41OR9510P (Melphalan); U68WG3173Y (Carmustine)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171201
[Lr] Data última revisão:
171201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170712
[St] Status:MEDLINE
[do] DOI:10.1002/pbc.26707


  8 / 6876 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28918185
[Au] Autor:Huis In 't Veld EA; Grünhagen DJ; Verhoef C; Smith HG; van Akkooi ACJ; Jones R; van Coevorden F; Hayes AJ; van Houdt WJ
[Ad] Endereço:Sarcoma Unit, Department of Surgery, Royal Marsden Hospital, London, United Kingdom; Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
[Ti] Título:Isolated limb perfusion for locally advanced angiosarcoma in extremities: A multi-centre study.
[So] Source:Eur J Cancer;85:114-121, 2017 Nov.
[Is] ISSN:1879-0852
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Angiosarcomas are rare and aggressive soft-tissue sarcomas. The only potential curative treatment is complete surgical excision. This study reports the outcome of isolated limb perfusion (ILP) with high-dose melphalan and tumour necrosis factor α for locally advanced angiosarcoma. MATERIAL AND METHODS: All patients who underwent an ILP for angiosarcomas between 1991 and 2016 in three tertiary referral centres were identified from prospectively maintained databases. RESULTS: A total of 39 patients were included, with a median follow-up of 18 months (interquartile range 6.1-60.8). Of these patients, 23 (58.9%) patients had a complete response (CR) after ILP, 10 (25.6%) had a partial response, 4 (10.3%) had stable disease and 2 (5.1%) patients had progressive disease immediately after ILP. A total of 22 patients developed local progression (56.4%), whereas nine (23.1%) developed distant metastases. The patients with CR had a significantly prolonged median local progression-free survival (PFS) (15.4 versus 7.3 months, p = 0.015) when compared with non-CR patients, and a trend towards better median overall survival (81.2 versus 14.5 months, p = 0.054). Six patients underwent multiple ILPs, whereby the CR rate of the first, second and third ILPs were 60%, 80% and 67%, respectively. Thirteen (33.3%) patients needed further surgical intervention, consisting of resection in eight patients (20.5%) and amputation in five patients (12.8%). CONCLUSION: ILP is an effective treatment option for patients with locally advanced angiosarcoma in the extremities, resulting in a high number of CRs, a high limb salvage rate and prolonged local PFS.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Quimioterapia do Câncer por Perfusão Regional/métodos
Extremidades/irrigação sanguínea
Hemangiossarcoma/irrigação sanguínea
Hemangiossarcoma/terapia
Melfalan/administração & dosagem
Neoplasias de Tecidos Moles/irrigação sanguínea
Neoplasias de Tecidos Moles/terapia
Fator de Necrose Tumoral alfa/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Amputação
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Quimioterapia do Câncer por Perfusão Regional/efeitos adversos
Quimioterapia do Câncer por Perfusão Regional/mortalidade
Bases de Dados Factuais
Progressão da Doença
Intervalo Livre de Doença
Extremidades/patologia
Feminino
Hemangiossarcoma/mortalidade
Hemangiossarcoma/secundário
Seres Humanos
Estimativa de Kaplan-Meier
Salvamento de Membro
Londres
Masculino
Melfalan/efeitos adversos
Meia-Idade
Países Baixos
Modelos de Riscos Proporcionais
Fluxo Sanguíneo Regional
Retratamento
Estudos Retrospectivos
Fatores de Risco
Neoplasias de Tecidos Moles/mortalidade
Neoplasias de Tecidos Moles/patologia
Fatores de Tempo
Resultado do Tratamento
Fator de Necrose Tumoral alfa/efeitos adversos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Tumor Necrosis Factor-alpha); Q41OR9510P (Melphalan)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170918
[St] Status:MEDLINE


  9 / 6876 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28879595
[Au] Autor:Partanen A; Valtola J; Ropponen A; Vasala K; Penttilä K; Ågren L; Pyörälä M; Nousiainen T; Selander T; Mäntymaa P; Pelkonen J; Varmavuo V; Jantunen E
[Ad] Endereço:Department of Medicine, Kuopio University Hospital, P.O.B. 100, 70029 KYS, Kuopio, Finland. anu.partanen@kuh.fi.
[Ti] Título:Preemptive plerixafor injection added to pegfilgrastim after chemotherapy in non-Hodgkin lymphoma patients mobilizing poorly.
[So] Source:Ann Hematol;96(11):1897-1906, 2017 Nov.
[Is] ISSN:1432-0584
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Filgrastim is usually combined with chemotherapy to mobilize hematopoietic progenitor cells in non-Hodgkin lymphoma (NHL) patients. Limited information is available on the efficacy of a preemptive plerixafor (PLER) injection in poor mobilizers after chemotherapy and pegfilgrastim. In this prospective study, 72 patients with NHL received chemotherapy plus pegfilgrastim, and 25 hard-to-mobilize patients received also PLER. The usefulness and efficacy of our previously developed algorithm for PLER use in pegfilgrastim-containing mobilization regimen were evaluated as well as the graft cellular composition, hematological recovery, and outcome after autologous stem cell transplantation (auto-SCT) according to the PLER use. A median 3.4-fold increase in blood CD34 cell counts was achieved after the first PLER dose. The minimum collection target was achieved in the first mobilization attempt in 66/72 patients (92%) and 68 patients (94%) proceeded to auto-SCT. An algorithm for PLER use was fulfilled in 76% of the poor mobilizers. Absolute numbers of T-lymphocytes and NK cells were significantly higher in the PLER group, whereas the number of CD34 cells collected was significantly lower. Early neutrophil engraftment was slower in the PLER group, otherwise hematological recovery was comparable within 12 months from auto-SCT. No difference was observed in survival according to the PLER use. Chemotherapy plus pegfilgrastim combined with preemptive PLER injection is an effective and convenient approach to minimize collection failures in NHL patients intended for auto-SCT. A significant effect of PLER on the graft cellular composition was observed, but no difference in outcome after auto-SCT was detected.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Fator Estimulador de Colônias de Granulócitos/administração & dosagem
Mobilização de Células-Tronco Hematopoéticas/tendências
Compostos Heterocíclicos/administração & dosagem
Linfoma não Hodgkin/terapia
[Mh] Termos MeSH secundário: Adulto
Idoso
Carmustina/administração & dosagem
Citarabina/administração & dosagem
Quimioterapia Combinada
Feminino
Filgrastim
Mobilização de Células-Tronco Hematopoéticas/métodos
Seres Humanos
Injeções Subcutâneas
Linfoma não Hodgkin/sangue
Linfoma não Hodgkin/diagnóstico
Masculino
Melfalan/administração & dosagem
Meia-Idade
Podofilotoxina/administração & dosagem
Polietilenoglicóis
Estudos Prospectivos
Proteínas Recombinantes/administração & dosagem
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Heterocyclic Compounds); 0 (Recombinant Proteins); 04079A1RDZ (Cytarabine); 143011-72-7 (Granulocyte Colony-Stimulating Factor); 155148-31-5 (JM 3100); 30IQX730WE (Polyethylene Glycols); 3A58010674 (pegfilgrastim); L36H50F353 (Podophyllotoxin); PVI5M0M1GW (Filgrastim); Q41OR9510P (Melphalan); U68WG3173Y (Carmustine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170908
[St] Status:MEDLINE
[do] DOI:10.1007/s00277-017-3123-6


  10 / 6876 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28850697
[Au] Autor:Sanchorawala V; McCausland KL; White MK; Bayliss MS; Guthrie SD; Lo S; Skinner M
[Ad] Endereço:Amyloidosis Center, Boston University School of Medicine, Boston, MA, USA.
[Ti] Título:A longitudinal evaluation of health-related quality of life in patients with AL amyloidosis: associations with health outcomes over time.
[So] Source:Br J Haematol;179(3):461-470, 2017 Nov.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Light chain (AL) amyloidosis is a rare disease associated with significant, irreversible organ dysfunction and high case fatality. An observational study was conducted to assess health-related quality of life (HRQoL) in patients treated for AL amyloidosis between 1994 and 2014 with both high dose melphalan and stem cell transplantation (HDM/SCT) or non-SCT chemotherapy regimens. The SF-36v1 Health Survey (SF-36) was administered to assess HRQoL during clinic visits. Analysis of variance was used to compare pre- and post-treatment HRQoL within each treatment group to an age- and gender-adjusted general population (GP) normative sample. Cox proportional hazard models were fit to examine associations between pre-treatment levels of HRQoL and mortality within 1 and 5 years after initiating specific treatment regimens (HDM/SCT: n = 402; non-SCT chemotherapy regimens: n = 172). Among patients who received HDM/SCT, there were significant improvements following treatment in vitality, social functioning, role-emotional and mental health. Worse pre-treatment SF-36 physical component scores were associated with a greater risk of mortality in both treatment groups and follow-up periods (P ≤ 0·005 for both). [Correction added on 20 October 2017, after first online publication: This P value has been corrected]. Using HRQoL assessments in every physician visit or treatment may provide valuable insights for treating rare conditions like AL amyloidosis.
[Mh] Termos MeSH primário: Amiloidose/terapia
Qualidade de Vida
[Mh] Termos MeSH secundário: Idoso
Amiloidose/mortalidade
Amiloidose/reabilitação
Feminino
Seres Humanos
Estimativa de Kaplan-Meier
Estudos Longitudinais
Masculino
Massachusetts/epidemiologia
Melfalan/uso terapêutico
Meia-Idade
Agonistas Mieloablativos/uso terapêutico
Psicometria
Estudos Retrospectivos
Transplante de Células-Tronco
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Myeloablative Agonists); Q41OR9510P (Melphalan)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171030
[Lr] Data última revisão:
171030
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170830
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.14889



página 1 de 688 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde